BioSpace News Archive

Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

Avail Medsystems, a medical technology company that is pioneering telemedicine for the procedure room, announced that it has been named by Fierce Medtech as one of 2020’s Fierce 15, designating it as one of the most promising private companies in the industry.

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced the advancement of its ongoing Phase 1 clinical study of Radspherin® in ovarian cancer patients suffering from peritoneal carcinomatosis to the third level dose cohort following approval from the trial Safety Monitoring Committee

Hyperfine Research has been named by Fierce Medtech as one of 2020’s Fierce 15, designating it as one of the most innovative and creative private companies in the industry with its category-defining Swoop™ Portable MR Imaging System.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, will be participating in the following virtual investor conferences.

This new EMA designation provides NervGen with multiple incentives, including improved access to scientific advice, fee reductions, and 10 years of protection from market competition in Europe from similar medicines with similar indications following the date that the drug candidate receives marketing authorization (called market exclusivity).

INNOVO adds significant incremental investment for pioneering home-based treatment for stress urinary incontinence, a condition that impacts 1 in 3 women worldwide Netherland’s Borski Fund backs female-led, femtech focused companies

Therapeutic Research Center, LLC, a portfolio company of Levine Leichtman Capital Partners, announced that it has acquired CE Resources, Inc., d/b/a NetCE.

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Dr. Caroline Kurtz to Chief Development Officer. As Chief Development Officer,

The group of concerned shareholders Concerned Shareholders of FSD Pharma Inc. which includes two founding directors, Anthony Durkacz and Zeeshan Saeed , are pleased to announce that they were successful in their request that the Ontario Superior Court of Justice order the Company to accelerate the date of its previously called annual shareholders meeting.